Praxis Precision Medicines, Inc. Common Stock
Symbol: PRAX (NASDAQ)
Company Description:
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
- Today's Open: $40.61
- Today's High: $42.52
- Today's Low: $38.895
- Today's Volume: 293.05K
- Yesterday Close: $40.03
- Yesterday High: $41.08
- Yesterday Low: $38
- Yesterday Volume: 720.38K
- Last Min Volume: 7.76K
- Last Min High: $40.81
- Last Min Low: $40.81
- Last Min VWAP: $40.81
- Name: Praxis Precision Medicines, Inc. Common Stock
- Website: https://www.praxismedicines.com
- Listed Date: 2020-10-16
- Location: BOSTON, MA
- Market Status: Active
- CIK Number: 0001689548
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $857.77M
- Round Lot: 100
- Outstanding Shares: 21.05M
- Asset Type: CS
Filing Date | Filing Type | Format |
---|---|---|
2025-09-05 | 8-K | View |
2025-09-05 | 424B5 | View |
2025-09-02 | SCHEDULE 13G/A | View |
2025-08-19 | 3 | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-14 | SCHEDULE 13G/A | View |
2025-08-12 | SCHEDULE 13G/A | View |
2025-08-05 | SCHEDULE 13G/A | View |
2025-08-04 | 8-K | View |
2025-08-04 | 10-Q | View |
2025-07-22 | SCHEDULE 13G | View |
2025-07-17 | 8-K | View |
2025-06-27 | 4 | View |
2025-06-27 | 4 | View |
2025-06-27 | 4 | View |
2025-06-27 | 4 | View |
2025-06-27 | 4 | View |
2025-06-27 | 4 | View |
2025-06-27 | 8-K | View |